Evidence map›Paper›PMID 25122198›Full record

ArticleCancer discovery2014

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Jared M Lucas, Cynthia Heinlein, Tom Kim, Susana A Hernandez, Muzdah S Malik, Lawrence D True, Colm Morrissey, Eva Corey, Bruce Montgomery, Elahe Mostaghel and 8 more

Open access · greenAbstract read
In one paragraph

Article in Cancer discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 302 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
302citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

302 citing papers in PubMed, 2 syntheses or guidelines pooled it, 488 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. COVID-19 Prophylactic Effect of Bromhexine Hydrochloride.Immunity, inflammation and disease · 2026
    Article
  8. Expression of angiotensin-converting enzyme 2, transmembrane serine protease 2, and sirtuin 1 proteins in lungs of different age groups.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

242 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Jared M LucasDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cynthia HeinleinDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Tom KimDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Susana A HernandezDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Muzdah S MalikDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Lawrence D TrueDepartment of Pathology, University of Washington, Seattle, Washington.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, Washington.
Eva CoreyDepartment of Urology, University of Washington, Seattle, Washington.
Bruce MontgomeryDepartment of Medicine, University of Washington, Seattle, Washington.
Elahe MostaghelDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Medicine, University of Washington, Seattle, Washington.
Nigel CleggDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Ilsa ColemanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Christopher M BrownDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Eric L SchneiderDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Charles CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Julian A SimonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Antonio BedalovDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Pathology, University of Washington, Seattle, Washington. Department of Urology, University of Washington, Seattle, Washington. Department of Medicine, University of Washington, Seattle, Washington. pnelson@fhcrc.org.
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Transmembrane Proteases and Prostate CarcinogenesisP01CA085859 · NCI · UNIVERSITY OF WASHINGTON · PI VESSELLA, ROBERT LOUIS · 2002 to 2013
$21.2M
Influences of the Microenvironment on Cancer Stem CellsU01CA164188 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NELSON, PETER S, WITTE, OWEN N. · 2011 to 2015
$2.9M
Resistance to Cancer Therapeutics Through Microenvironment Damage Responses.R01CA165573 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2012 to 2016
$1.8M
NCI NIH HHS P01 CA085859NCI NIH HHS P01CA85859NCI NIH HHS P50 CA097186NCI NIH HHS P50CA97186NCI NIH HHS R01 CA165573NCI NIH HHS R01CA165573NCI NIH HHS U01 CA164188NCI NIH HHS U01CA164188
6 · The paper itself

Abstract

unlabelledTMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted deletion of Tmprss2, we demonstrate that the activity of this protease regulates cancer cell invasion and metastasis to distant organs. By screening combinatorial peptide libraries, we identified a spectrum of TMPRSS2 substrates that include pro-hepatocyte growth factor (HGF). HGF activated by TMPRSS2 promoted c-MET receptor tyrosine kinase signaling, and initiated a proinvasive epithelial-to-mesenchymal transition phenotype. Chemical library screens identified a potent bioavailable TMPRSS2 inhibitor that suppressed prostate cancer metastasis in vivo. Together, these findings provide a mechanistic link between androgen-regulated signaling programs and prostate cancer metastasis that operate via context-dependent interactions with extracellular constituents of the tumor microenvironment. SIGNIFICANCE: The vast majority of prostate cancer deaths are due to metastasis. Loss of TMPRSS2 activity dramatically attenuated the metastatic phenotype through mechanisms involving the HGF-c-MET axis. Therapeutic approaches directed toward inhibiting TMPRSS2 may reduce the incidence or progression of metastasis in patients with prostate cancer.

Indexed as

AndrogensAnimalsCell Line, TumorHepatocyte Growth FactorHumansMaleMice, KnockoutMice, SCIDPeptide LibraryProstatic NeoplasmsProteolysisProto-Oncogene Proteins c-metReceptors, AndrogenSerine EndopeptidasesTumor MicroenvironmentAndrogensHepatocyte Growth FactorPeptide LibraryProto-Oncogene Proteins c-metReceptors, AndrogenSerine EndopeptidasesTMPRSS2 protein, mouse

Identifiers

PMID25122198
PMCPMC4409786
OpenAlexW2134872401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.